Adaptive Radiation Boost for Rectal Cancer

Recruiting Phase 1 Interventional Study
Rectum Cancer, Adenocarcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
37 (estimated)
Sponsor
Fox Chase Cancer Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer. The main questions the study aims to answer are: * Can this approach help target the most aggressive cancer cells more accurately, while protecting nearby healthy tissue? * Can it reduce the side effects that people m…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Subjects must have histologically or cytologically confirmed rectal adenocarcinoma. 2. Subjects must have T2-3, N0-1, M0 rectal cancer. Staging will be done by MRI pelvis and CT chest and abdomen with contrast. PET-CT will be an acceptable alternative for the CT chest and abd…
Contacts

Joshua Meyer, MD

215-728-2667

Joshua.Meyer@fccc.edu

CONTACT

Jianli Hu, MD, PhD

267-449-1431

Jianli.Hu@fccc.edu

CONTACT